• Fights ulcer in the upper part of the intestine (duodenal ulcer) and benign stomach ulcer.
• Relieves gastro-oesophageal reflux disease (GORD) with or without ulcer
• Combats Zollinger-Ellison Syndrome, which is a condition when the stomach makes extremely high amounts of acid.
• When used with a combination with antibiotics, Rabeprazole can fight of H. pylori infection in patients with peptic ulcerdisease.
• Relieves upper Gastro-intestinal Bleeding
• Prevents Acid-Aspiration during Surgery
• Treats Stress-induced mucosal injury

You must avoid using Rabeloc if you are:

• are allergic to Rabeprazole or any of the ingredients in Rabeloc
• are allergic to proton pump inhibitors (PPI)

It is advisable to talk to your doctor before taking Rabeloc or any Rabeprazole drug.

Warnings
Doctors have prescribed Rabeloc to millions of patients to treat acid-related conditions safely over the years.

The safety of Rabeloc is already confirmed from many clinical trials with Rabeprazole in Tablet and injectable formulation. Since it is a Prescription drug, read package insert carefully before using. Inform your doctor/pharmacist of any side effects immediately &Keep away from children. For more information please contact your doctor.

As with any other drug, there can be side-effects of using Rabeloc. However, not many would experience the adverse effects of Rabeprazole.

The side effects experienced are usually mild but it may improve without stopping to take this medicine. Please consult your doctor and ask about possible side effects.

Global Pharmacovigilance Department
The Global Pharmacovigilance department prioritize the patient safety by monitoring the safety of Cadila products. Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine related problem. Global Pharmacovigilance takes an extensive approach to pharmacovigilance activities to establish, maintain, and communicate quality safety information throughout the life cycle of Cadila products.

In compliance with the applicable worldwide regulations, Cadila is committed to collect, review, and evaluate information regarding adverse events, product complaints, and other safety findings experienced by clinical trial subjects who receive our investigational drugs and by patients taking our approved products. This information helps us better understand, assess, and communicate the safety profile of Cadila products and allows us to deliver safer products to patients.

Adverse Event and Product Complaint Reporting
At Cadila Pharmaceuticals, we are committed to providing world-class medicines and understand the need for and importance of monitoring drug safety. It is Cadila's policy to comply with all regulations and laws worldwide relating to reporting adverse events, other safety finding and product complaints. Individuals are required to report adverse event, other safety finding and product complaint within one business day.

What information you need to report an Adverse Event
When reporting an adverse event, other safety finding or product complaint, you will need at to have the following information ready:

• An identifiable patient: The person who has taken or been administered the product (e.g. age, gender, etc.), in compliance with local privacy laws.
• An identifiable reporter: The source that reported the event (e.g. patient, health care provider, friend, etc.), in compliance with local privacy laws.
• The medicinal product: Cadila product name, indication and lot number if known.
• The reportable event: Description of the AE, other safety finding or product complaint.

What to report:

• All types of adverse events (side effects occurring after administration of drug)
• Other scenario/situations (even if not associated with adverse event): Overdose, Accidental use, Abuse and misuse, Medication errors, Use of drug during breast feeding, Paternal exposure, Lack of efficacy, Unexpected therapeutic or clinical benefit, Use of drug in unapproved indication, Use of drug during pregnancy, Drug interactions

Who can report:
Report even if:

• You are not certain whether the medicine caused an adverse reaction or not
• You don’t have all the required details

How to report?
Contact patient safety at:
Sarkhej-Dholka Road, Bhat, Ahmedabad-382 210, INDIA.
Phone : +91-2718-251334
Email: safety.cadila.global@cadilapharma.co.in
For detailed reporting click to download

Adverse Event Reporting Form